{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:23:29Z","timestamp":1780676609488,"version":"3.54.1"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UH2AA026218, UL1TR002529"],"award-info":[{"award-number":["UH2AA026218, UL1TR002529"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["53183, OPP1035237"],"award-info":[{"award-number":["53183, OPP1035237"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoints (ICPs) consist of paired receptor-ligand molecules that exert inhibitory or stimulatory effects on immune defense, surveillance, regulation, and self-tolerance. ICPs exist in both membrane and soluble forms\n                    <jats:italic>in vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Imbalances between inhibitory and stimulatory membrane-bound ICPs (mICPs) in malignant cells and immune cells in the tumor immune microenvironment (TIME) have been well documented. Blockades of inhibitory mICPs have emerged as an immense breakthrough in cancer therapeutics. However, the origin, structure, production regulation, and biological significance of soluble ICPs (sICPs) in health and disease largely remains elusive. Soluble ICPs can be generated through either alternative mRNA splicing and secretion or protease-mediated shedding from mICPs. Since sICPs are found in the bloodstream, they likely form a circulating immune regulatory system. In fact, there is increasing evidence that sICPs exhibit biological functions including (1) regulation of antibacterial immunity, (2) interaction with their mICP compartments to positively or negatively regulate immune responses, and (3) competition with their mICP compartments for binding to the ICP blocking antibodies, thereby reducing the efficacy of ICP blockade therapies. Here, we summarize current data of sICPs in cancer and infectious diseases. We particularly focus on sICPs in COVID-19 and HIV infection as they are the two ongoing global pandemics and have created the world\u2019s most serious public health challenges. A \u201cstorm\u201d of sICPs occurs in the peripheral circulation of COVID-19 patients and is associated with the severity of COVID-19. Similarly, sICPs are highly dysregulated in people living with HIV (PLHIV) and some sICPs remain dysregulated in PLHIV on antiretroviral therapy (ART), indicating these sICPs may serve as biomarkers of incomplete immune reconstitution in PLHIV on ART. We reveal that HIV infection in the setting of alcohol misuse exacerbates sICP dysregulation as PLHIV with heavy alcohol consumption have significantly elevated plasma levels of many sICPs. Thus, both stimulatory and inhibitory sICPs are present in the bloodstream of healthy people and their balance can be disrupted under pathophysiological conditions such as cancer, COVID-19, HIV infection, and alcohol misuse. There is an urgent need to study the role of sICPs in immune regulation in health and disease.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.833310","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T02:49:32Z","timestamp":1645584572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahim","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan F.","family":"Relich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Kacena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced Expression of PD-1, A Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune Checkpoint Blockade in Infectious Diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune Checkpoints and Their Inhibition in Cancer and Infectious Diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 Expression on HIV-Specific CD8+ T Cells Leads to Reversible Immune Dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-Specific CD4+ T Cells Correlates With Disease Progression and Defines a Reversible Immune Dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT Marks Exhausted T Cells, Correlates With Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection","volume":"12","author":"Chew","year":"2016","journal-title":"PloS Pathog"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune Checkpoint Blockade Therapy for Cancer: An Overview of FDA-Approved Immune Checkpoint Inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100005","article-title":"Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment","volume":"35","author":"Berghoff","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors Per NCCN Guidelines With the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092227","article-title":"Immune Checkpoint Inhibitors in People Living With HIV\/AIDS: Facts and Controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 Therapy for Infectious Diseases: Learning From the Cancer Paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061496","article-title":"PD-1 Is a Regulator of Virus-Specific CD8+ T Cell Survival in HIV Infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 Expression on HIV-Specific T Cells Is Associated With T-Cell Exhaustion and Disease Progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 Co-Inhibitory Pathway in HIV Infection and Potential Therapeutic Options","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072000","article-title":"Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection","volume":"19","author":"Sperk","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PloS Pathog"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000913","article-title":"Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion That Broadly Characterize Immune Failure in Treated HIV Infection","volume":"71","author":"Shive","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1038\/ncomms9495","article-title":"Immunological Biomarkers Predict HIV-1 Viral Rebound After Treatment Interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence During ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PloS Pathog"},{"key":"B27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV Reservoir Size and Persistence Are Driven by T Cell Survival and Homeostatic Proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of Ipilimumab on the HIV Reservoir in an HIV-Infected Individual With Metastatic Melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-Specific T Cells Increase and Inflammation in an HIV-Infected Patient Treated With Nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic Decrease of the HIV Reservoir in a Patient Treated With Nivolumab for Lung Cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0426-6","article-title":"Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions","volume":"75","author":"Polizzotto","year":"2015","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/737389","article-title":"PD-1 Blockade in Advanced Melanoma in Patients With Hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9867-9","article-title":"Immune Checkpoint Receptors: Homeostatic Regulators of Immunity","volume":"12","author":"Riva","year":"2018","journal-title":"Hepatol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.01.008","article-title":"Soluble Tim-3 and Gal-9 Are Associated With Renal Allograft Dysfunction in Kidney Transplant Recipients: A Cross-Sectional Study","volume":"55","author":"Li","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6670","article-title":"Noninvasive Detection of Acute Renal Allograft Rejection by Measurement of Soluble Tim-3 in Urine","volume":"16","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-016-1075-1","article-title":"Immunoregulatory Soluble CTLA-4 Modifies Effector T-Cell Responses in Systemic Lupus Erythematosus","volume":"18","author":"Dahal","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12653","article-title":"Plasma Soluble Tim-3 Emerges as an Inhibitor in Sepsis: Sepsis Contrary to Membrane Tim-3 on Monocytes","volume":"86","author":"Ren","year":"2015","journal-title":"Tissue Antigens"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/215763","article-title":"The Soluble Form of CTLA-4 From Serum of Patients With Autoimmune Diseases Regulates T-Cell Responses","volume":"2014","author":"Simone","year":"2014","journal-title":"BioMed Res Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2728","article-title":"Soluble Human LAG-3 Molecule Amplifies the In Vitro Generation of Type 1 Tumor-Specific Immunity","volume":"66","author":"Casati","year":"2006","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0204","article-title":"A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation","volume":"2","author":"Haile","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: Predictive and Prognostic Significance in Cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2012.44.2.010","article-title":"The Presence of High Level Soluble Herpes Virus Entry Mediator in Sera of Gastric Cancer Patients","volume":"44","author":"Heo","year":"2012","journal-title":"Exp Mol Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble Immune Checkpoints in Cancer: Production, Function and Biological Significance","volume":"6","author":"Gu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5015","article-title":"Cutting Edge: A Soluble Form of CTLA-4 in Patients With Autoimmune Thyroid Disease","volume":"164","author":"Oaks","year":"2000","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep4.1475","article-title":"Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis","volume":"4","author":"Li","year":"2020","journal-title":"Hepatol Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.2000.1649","article-title":"A Native Soluble Form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A New Member of the Immunoglobulin Superfamily\u2013CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A Moving Target in Immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90816-W","article-title":"Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor","volume":"61","author":"Schall","year":"1990","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830181133","article-title":"Demonstration of Two Distinct Forms of Released Low-Affinity Type Interleukin 2 Receptors","volume":"18","author":"Josimovic-Alasevic","year":"1988","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90295-X","article-title":"The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms","volume":"59","author":"Mosley","year":"1989","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90342-C","article-title":"Cloning of the Human and Murine Interleukin-7 Receptors: Demonstration of a Soluble Form and Homology to a New Receptor Superfamily","volume":"60","author":"Goodwin","year":"1990","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.5.11.1868981","article-title":"Soluble Cytokine Receptors: Their Role in Immunoregulation","volume":"5","author":"Fernandez-Botran","year":"1991","journal-title":"FASEB J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5343","article-title":"Mechanisms of Soluble Cytokine Receptor Generation","volume":"173","author":"Levine","year":"2004","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81363-X","article-title":"Herpes Simplex Virus-1 Entry Into Cells Mediated by a Novel Member of the TNF\/NGF Receptor Family","volume":"87","author":"Montgomery","year":"1996","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0241-1","article-title":"HVEM, a Cosignaling Molecular Switch, and Its Interactions With BTLA, CD160 and LIGHT","volume":"16","author":"Rodriguez-Barbosa","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500637","article-title":"Neuron-Specific SALM5 Limits Inflammation in the CNS via Its Interaction With HVEM","volume":"2","author":"Zhu","year":"2016","journal-title":"Sci Adv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.632502","article-title":"Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-Bacterial Immunity","volume":"12","author":"Riva","year":"2021","journal-title":"Front Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587460","article-title":"Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50256","article-title":"Soluble PD-L1 Generated by Endogenous Retroelement Exaptation Is a Receptor Antagonist","volume":"8","author":"Ng","year":"2019","journal-title":"Elife"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41598-020-60440-5","article-title":"Clinical Significance of Circulating Soluble Immune Checkpoint Proteins in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma","volume":"10","author":"Dong","year":"2020","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-020-6612-2","article-title":"Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1) in Patients With Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"20","author":"Cho","year":"2020","journal-title":"BMC Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-181278","article-title":"Soluble LAG3 Acts as a Potential Prognostic Marker of Gastric Cancer and Its Positive Correlation With CD8+T Cell Frequency and Secretion of IL-12 and INF-Gamma in Peripheral Blood","volume":"23","author":"Li","year":"2018","journal-title":"Cancer biomark"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S162478","article-title":"Highly Elevated Soluble Tim-3 Levels Correlate With Increased Hepatocellular Carcinoma Risk and Poor Survival of Hepatocellular Carcinoma Patients in Chronic Hepatitis B Virus Infection","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044654","article-title":"A Soluble Form of CTLA-4 Is Present in Paediatric Patients With Acute Lymphoblastic Leukaemia and Correlates With CD1d+ Expression","volume":"7","author":"Simone","year":"2012","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0348-03","article-title":"Soluble CD40 Ligand Plasma Levels in Lung Cancer","volume":"10","author":"Roselli","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-9378-2-5","article-title":"High Serum Levels of Soluble CD40-L in Patients With Undifferentiated Nasopharyngeal Carcinoma: Pathogenic and Clinical Relevance","volume":"2","author":"Caggiari","year":"2007","journal-title":"Infect Agent Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/35393","article-title":"CD40 Ligand on Activated Platelets Triggers an Inflammatory Reaction of Endothelial Cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2010_02_145","article-title":"Platelet Activation in Patients With Advanced Gastric Cancer","volume":"57","author":"Osada","year":"2010","journal-title":"Neoplasma"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.1465616","article-title":"Alterations in Signal Transduction Molecules in T Lymphocytes From Tumor-Bearing Mice","volume":"258","author":"Mizoguchi","year":"1992","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-427799","article-title":"Elevated Serum Soluble CD40 Ligand in Cancer Patients May Play an Immunosuppressive Role","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2005.07.007","article-title":"Alternative Splice Variants of the Human PD-1 Gene","volume":"235","author":"Nielsen","year":"2005","journal-title":"Cell Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2012.13.8.4031","article-title":"Reconstructed Adeno-Associated Virus With the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity","volume":"13","author":"Elhag","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.010","article-title":"Eliminating Mesothelioma by AAV-Vectored, PD1-Based Vaccination in the Tumor Microenvironment","volume":"20","author":"Tan","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1160","article-title":"Soluble Immune Checkpoint Molecules: Serum Markers for Cancer Diagnosis and Prognosis","volume":"2","author":"Chakrabarti","year":"2019","journal-title":"Cancer Rep (Hoboken)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182395","article-title":"Development of Immune Checkpoint Therapy for Cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-020-00308-2","article-title":"Storm of Soluble Immune Checkpoints Associated With Disease Severity of COVID-19","volume":"5","author":"Kong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1002\/ctm2.573","article-title":"The Immune Checkpoints Storm in COVID-19: Role as Severity Markers at Emergency Department Admission","volume":"11","author":"Avendano-Ortiz","year":"2021","journal-title":"Clin Transl Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of Data of 150 Patients From Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex Immune Dysregulation in COVID-19 Patients With Severe Respiratory Failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","article-title":"Lymphopenia Predicts Disease Severity of COVID-19: A Descriptive and Predictive Study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244","article-title":"Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40560-020-00453-4","article-title":"Lymphopenia in Severe Coronavirus Disease-2019 (COVID-19): Systematic Review and Meta-Analysis","volume":"8","author":"Huang","year":"2020","journal-title":"J Intensive Care"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8511","article-title":"Deep Immune Profiling of COVID-19 Patients Reveals Distinct Immunotypes With Therapeutic Implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108486","article-title":"Selective CD8 Cell Reduction by SARS-CoV-2 Is Associated With a Worse Prognosis and Systemic Inflammation in COVID-19 Patients","volume":"217","author":"Urra","year":"2020","journal-title":"Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.06.013","article-title":"Lymphopenia During the COVID-19 Infection: What It Shows and What Can Be Learned","volume":"225","author":"Tavakolpour","year":"2020","journal-title":"Immunol Lett"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652470","article-title":"Neutrophils in COVID-19","volume":"12","author":"Reusch","year":"2021","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"B94","first-page":"189","article-title":"Relationships Among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in Coronavirus (COVID-19) Infected Patients","volume-title":"Br J Haematol","author":"Wan","year":"2020"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.1101\/2020.07.28.225912","article-title":"Infection of Human Lymphomononuclear Cells by SARS-CoV-2","volume-title":"bioRxiv","author":"Pontelli","year":"2020"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0402-6","article-title":"T Cell Responses in Patients With COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3024","article-title":"Distinct Inflammatory Profiles Distinguish COVID-19 From Influenza With Limited Contributions From Cytokine Storm","volume":"6","author":"Mudd","year":"2020","journal-title":"Sci Adv"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110053","article-title":"Rethinking Interleukin-6 Blockade for Treatment of COVID-19","volume":"144","author":"Scherger","year":"2020","journal-title":"Med Hypotheses"},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.17052","article-title":"Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions","volume-title":"JAMA","author":"Kox","year":"2020"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab167","article-title":"Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19","volume-title":"J Infect Dis","author":"Syed","year":"2021"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \"Cytokine Storm\" Relevant to COVID-19","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.it.2020.11.002","article-title":"T Cells: Warriors of SARS-CoV-2 Infection","volume":"42","author":"de Candia","year":"2021","journal-title":"Trends Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0536-x","article-title":"Pathological Study of the 2019 Novel Coronavirus Disease (COVID-19) Through Postmortem Core Biopsies","volume":"33","author":"Tian","year":"2020","journal-title":"Mod Pathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2003","article-title":"Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0602-4","article-title":"COVID-19 Severity Correlates With Airway Epithelium-Immune Cell Interactions Identified by Single-Cell Analysis","volume":"38","author":"Chua","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1371\/journal.pbio.0020020","article-title":"Immune Activation and CD8+ T-Cell Differentiation Towards Senescence in HIV-1 Infection","volume":"2","author":"Papagno","year":"2004","journal-title":"PloS Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T Cell Exhaustion During Persistent Viral Infections","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12823","article-title":"T-Cell Exhaustion in HIV Infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02109","article-title":"Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology","volume":"10","author":"Mylvaganam","year":"2019","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020065","article-title":"Soluble PD-L1: A Potential Immune Marker for HIV-1 Infection and Virological Failure","volume":"99","author":"Avendano-Ortiz","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/ITT.S163614","article-title":"Multiple Effects of CD40-CD40L Axis in Immunity Against Infection and Cancer","volume":"7","author":"Ara","year":"2018","journal-title":"Immunotargets Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular Mechanism and Function of CD40\/CD40L Engagement in the Immune System","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228533","article-title":"CD40\/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection","volume":"21","author":"Daub","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"crossref","DOI":"10.1189\/jlb.68.3.373","article-title":"The Emerging Role of CD40 Ligand in HIV Infection","volume":"68","author":"Kornbluth","year":"2000","journal-title":"J\u00a0Leukoc Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0403171","article-title":"Role of CD40 Ligand Dysregulation in HIV-Associated Dysfunction of Antigen-Presenting Cells","volume":"74","author":"Chougnet","year":"2003","journal-title":"J Leukoc Biol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02035-18","article-title":"Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions","volume":"93","author":"Garcia-Bates","year":"2019","journal-title":"J Virol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and Autoimmunity: The Dark Side of a Great Activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L Pathway in Autoimmune Diseases: Humoral Immunity and Beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0809590","article-title":"HVEM\/LIGHT\/BTLA\/CD160 Cosignaling Pathways as Targets for Immune Regulation","volume":"87","author":"del Rio","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00783.x","article-title":"The CD160, BTLA, LIGHT\/HVEM Pathway: A Bidirectional Switch Regulating T-Cell Activation","volume":"229","author":"Cai","year":"2009","journal-title":"Immunol Rev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/ni1554","article-title":"CD160 Inhibits Activation of Human CD4+ T Cells Through Interaction With Herpesvirus Entry Mediator","volume":"9","author":"Cai","year":"2008","journal-title":"Nat Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/add.12899","article-title":"Global Statistics on Addictive Behaviours: 2014 Status Report","volume":"110","author":"Gowing","year":"2015","journal-title":"Addiction"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.70","article-title":"Alcohol: Taking a Population Perspective","volume":"13","author":"Gilmore","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23258","article-title":"Practice Guideline Committee of the American Association for the Study of Liver, D. & Practice Parameters Committee of the American College of, G. Alcoholic Liver Disease","volume":"51","author":"O'Shea","year":"2010","journal-title":"Hepatology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.17061\/phrp2641640","article-title":"Alcohol Consumption: Monitoring, Regulation and Impact on Public Health","volume":"26","author":"Mitchell","year":"2016","journal-title":"Public Health Res Pract"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153027","article-title":"Health Warnings on Alcoholic Beverages: Perceptions of the Health Risks and Intentions Towards Alcohol Consumption","volume":"11","author":"Wigg","year":"2016","journal-title":"PloS One"},{"key":"B132","article-title":"HIV Data and Statistics","volume-title":"HIV\/AIDS Fact Sheets","year":"2021"},{"key":"B133","article-title":"HIV\/AIDS, Comorbidity, and Alcohol: Can We Make a Difference","volume":"33","author":"Justice","year":"2010","journal-title":"Alcohol Res Health"},{"key":"B134","article-title":"Effects of Alcohol and HIV Infection on the Central Nervous System","volume":"25","author":"Meyerhoff","year":"2001","journal-title":"Alcohol Res Health"},{"key":"B135","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/00952990.2016.1211667","article-title":"Immune Activation and Neuroinflammation in Alcohol Use and HIV Infection: Evidence for Shared Mechanisms","volume":"43","author":"Monnig","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00236.2013","article-title":"Ethanol Disrupts Intestinal Epithelial Tight Junction Integrity Through Intracellular Calcium-Mediated Rho\/ROCK Activation","volume":"306","author":"Elamin","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1097\/01.alc.0000189280.19073.28","article-title":"Activation of the Innate Immune System and Alcoholic Liver Disease: Effects of Ethanol Per Se or Enhanced Intestinal Translocation of Bacterial Toxins Induced by Ethanol","volume":"29","author":"Bode","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets","volume":"141","author":"Gao","year":"2011","journal-title":"Gastroenterology"},{"key":"B139","article-title":"Impact of Alcohol Abuse on the Adaptive Immune System","volume":"37","author":"Pasala","year":"2015","journal-title":"Alcohol Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00537.2010","article-title":"Innate Immunity in Alcoholic Liver Disease","volume":"300","author":"Gao","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2010.01399.x","article-title":"Molecular Mechanisms of Alcoholic Liver Disease: Innate Immunity and Cytokines","volume":"35","author":"Miller","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29242","article-title":"Alcohol Abstinence Ameliorates the Dysregulated Immune Profiles in Patients With Alcoholic Hepatitis: A Prospective Observational Study","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/nm1511","article-title":"Microbial Translocation Is a Cause of Systemic Immune Activation in Chronic HIV Infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/infdis\/jiu409","article-title":"Intestinal Microbiota, Microbial Translocation, and Systemic Inflammation in Chronic HIV Infection","volume":"211","author":"Dinh","year":"2015","journal-title":"J Infect Dis"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.cgh.2016.05.041","article-title":"Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis","volume":"14","author":"Liangpunsakul","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29623","article-title":"The Circulating Microbiome Signature and Inferred Functional Metagenomics in Alcoholic Hepatitis","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41598-017-04669-7","article-title":"Quantity of Alcohol Drinking Positively Correlates With Serum Levels of Endotoxin and Markers of Monocyte Activation","volume":"7","author":"Liangpunsakul","year":"2017","journal-title":"Sci Rep"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000052","article-title":"Alcohol Abstinence Does Not Fully Reverse Abnormalities of Mucosal-Associated Invariant T Cells in the Blood of Patients With Alcoholic Hepatitis","volume":"10","author":"Li","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/imm.12673","article-title":"The Role of Mucosal-Associated Invariant T Cells in Infectious Diseases","volume":"150","author":"Wong","year":"2017","journal-title":"Immunology"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1038\/cti.2016.51","article-title":"MAIT Cells: New Guardians of the Liver","volume":"5","author":"Kurioka","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5159","article-title":"Immune-Checkpoint Inhibitors From Cancer to COVID19: A Promising Avenue for the Treatment of Patients With COVID19 (Review)","volume":"58","author":"Vivarelli","year":"2021","journal-title":"Int J Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082237","article-title":"Cancer Management During COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial","volume":"12","author":"Vivarelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001145","article-title":"On the Use of Immune Checkpoint Inhibitors in Patients With Viral Infections Including COVID-19","volume":"8","author":"Gambichler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1887131","article-title":"Immune Checkpoint Inhibition in COVID-19: Risks and Benefits","volume":"21","author":"Pezeshki","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s3355","article-title":"Abatacept in Difficult-to-Treat Juvenile Idiopathic Arthritis","volume":"2","author":"Kuemmerle-Deschner","year":"2008","journal-title":"Biologics"},{"key":"B158","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-019-0319-4","article-title":"Intravenous Abatacept in Japanese Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study","volume":"17","author":"Hara","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S146076","article-title":"Abatacept for the Treatment of Adults With Psoriatic Arthritis: Patient Selection and Perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 Coreceptor Expression and Signal Transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.833310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T13:58:36Z","timestamp":1674827916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.833310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2022.833310"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.833310","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.22.21268218","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"article-number":"833310"}}